Chemical type
- Immunotherapy agent (PD-1 inhibitor)
- Monoclonal antibody
- Immune checkpoint inhibitor
- PD-1 receptor inhibitor
Key properties
- Can induce exogenous cyclic ACTH-dependent Cushing syndrome
- Blocks programmed cell death protein 1 (PD-1)
- Enhances T-cell–mediated immune response
- Biologic immunotherapy agent
- Administered intravenously
- Cancer treatment (e.g., melanoma)
- Associated with endocrine side effects like cyclic Cushing
- Treatment of various advanced cancers
- Investigated in combination with olaparib for mCRPC
- Immunotherapy for biomarker-unselected metastatic prostate cancer
Classification by use
- Immunotherapies
- Medications causing endocrine disorders
- Chemicals used as immune checkpoint inhibitors
- Chemicals used in cancer immunotherapy
- Biologic agents used in combination cancer therapy
A trustworthy factory and manufacturer
Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.
- [Cite:1] Osilodrostat for Cyclic Cushing Disease, AACE Endocrinology and Diabetes, Volume 13, Issue 1, January–February 2026, Pages 17-21
- [Cite:2] PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis, European Urology Open Science, Volume 84, February 2026, Pages 1-12
